samedan logo
 
 
spacer
home > epc > summer 2018 > innovative indication
PUBLICATIONS
European Pharmaceutical Contractor

Innovative Indication

In the early days, biomarkers were used primarily as physiological indicators for blood pressure or heart rate, as examples. A biomarker is an objective indication of a particular medical state observed from outside the patient, which can be measured accurately and reproducibly.

More recently, biomarkers, such as elevated prostate specific antigen, can be used as a molecular biomarker for prostate cancer or enzyme assays used as liver function tests. A biomarker is anything that can be used as an indicator of a disease state or some other physiological state of an organism.

According to Strimbu and Jorge, the use of biomarkers in basic and clinical research, as well as in clinical practice, has become so commonplace that their presence as primary endpoints in clinical trials is now accepted almost without question (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Professor Christene Leiper attended Sydney University, RMIT Melbourne, and Bond University, Australia, and achieved a Professorship of Medicine and Life Sciences at Bond University in 2006. She also undertook research at Edinburgh University, Scotland, as part of her PhD. Christene has been a principal investigator for clinical trials, which enables her to operate across many disciplinary boundaries within clinical research in a coherent and productive manner. In 2007, she was appointed Director of Research at a Scottish CRO, which, in turn, led her to start her own CRO, Onorach, in 2009.
spacer
Professor Christene Leiper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Digital Health and Wearables

• Datwyler uses strategic partnerships to develop new solutions in the fields of wearables and digital health. • The company’s health care offering is always designed towards improving the comfort of patients during treatment. • The product portfolio and innovative healthcare solutions will be presented at several important trade fairs of the medical sector.
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

 
Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement